Adam JacksonJanuary 5, 2024
The move marks a departure from the firm's previous reliance on philanthropic funding.
Category: Psychedelics
Adam JacksonJanuary 5, 2024Adam JacksonJanuary 5, 2024
Functional mushrooms have seen a significant spike in interest since last summer, a development that analysts say is a result of rising interest for natural health products in general. According to a recent Brightfield Group report, these mushrooms, which are believed to help the body manage stress, used to be considered niche health food items, […]
Debra BorchardtJanuary 4, 2024
Beckley Psytech focuses on short duration psychedelic drug treatments.
Adam JacksonJanuary 3, 2024
The firm is targeting the FDA’s 505(b)(2) pathway for a potentially expedited approval process.
Adam JacksonJanuary 3, 2024
A medical cannabis pilot program was left out of the final bill.
Adam JacksonJanuary 2, 2024
The firm managed to find adequate research funding over the year as sale talks emerged.
Debra BorchardtJanuary 2, 2024
The company is a going concern, with a cumulative deficit of $4,132,349 as of August 31.
Jenel Stelton-HoltmeierDecember 20, 2023
The deal was terminated after additional changes were needed to meet Nasdaq listing requirements.
Adam JacksonDecember 15, 2023
Awakn partnered with Orphan Insight Ltd., which provides consulting on bringing novel drug therapies to market.
Debra BorchardtDecember 14, 2023
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). MindMed said that its trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety rating scale (HAM-A) compared to […]
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.